Ani Pharmaceuticals (ANIP) Retained Earnings (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Retained Earnings data on file, last reported at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 77.09% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 77.09% YoY), and the FY2025 full-year result was $596.0 million, up 11053.37% from the prior year.
• Retained Earnings fell to $6.4 million in Q1 2026, from $596.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $596.0 million in Q4 2025 to a low of -$97.3 million in Q4 2022.
• A 5-year average of $98.2 million and a median of $6.4 million in 2026 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings plunged 1439.3% in 2022 and jumped 11053.37% in 2025, its largest moves.
• Tracing ANIP's Retained Earnings over 5 years: stood at -$97.3 million in 2022, then surged by 109.1% to $8.9 million in 2023, then slumped by 39.66% to $5.3 million in 2024, then jumped by 11053.37% to $596.0 million in 2025, then slumped by 98.93% to $6.4 million in 2026.
• Business Quant data shows ANIP's Retained Earnings at $6.4 million in Q1 2026, $596.0 million in Q4 2025, and $2.8 million in Q3 2025.